Genetic modifiers of liver disease in cystic fibrosis

JAMA

Volumn 302, Issue 10, 2009, Pages 1076-1083

  Bartlett, Jaclyn R ^a   Friedman, Kenneth J ^c   Ling, Simon C ^d,e   Pace, Rhonda G ^a   Bell, Scott C ^f   Bourke, Billy ^g   Castaldo, Giuseppe ⁱ   Castellani, Carlo ^j   Cipolli, Marco ^j   Colombo, Carla ^k   Colombo, John L ^l   Debray, Dominique ^m   Fernandez, Adriana ⁿ   Lacaille, Florence ^o   Macek, Milan ^p   Rowland, Marion ^g,h   Salvatore, Francesco ⁱ   Taylor, Christopher J ^q   Wainwright, Claire ^r   Wilschanski, Michael ^s   Zemková, Dana ^p   Hannah, William B ^a   Phillips, M James ^d   Corey, Mary ^d,e   Zielenski, Julian ^d   Dorfman, Ruslan ^d   Wang, Yunfei ^a,b   Zou, Fei ^b   Silverman, Lawrence M ^t   Drumm, Mitchell L ^u   Wright, Fred A ^b   Lange, Ethan M ^a,b   Durie, Peter R ^d,e   Knowles, Michael R ^a   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b IL   (United States)

^c LABORATORY CORPORATION OF AMERICA   (United States)

^d HOSPITAL FOR SICK CHILDREN   (Canada)

^e UNIVERSITY OF TORONTO   (Canada)

^f THE PRINCE CHARLES HOSPITAL   (Australia)

^g OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^h UNIVERSITY COLLEGE DUBLIN   (Ireland)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^j UNIVERSITY HOSPITAL OF VERONA   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^m BICÊTRE HOSPITAL   (France)

ⁿ La Plata Children's Hospital   (Argentina)

^o HÔPITAL NECKER ENFANTS MALADES   (France)

^p UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^q UNIVERSITY OF SHEFFIELD   (United Kingdom)

^r ROYAL CHILDREN'S HOSPITAL   (Australia)

^s HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^t UNIVERSITY OF VIRGINIA   (United States)

^u CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALPHA 1 ANTITRYPSIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; DIPEPTIDYL CARBOXYPEPTIDASE; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE TRANSFERASE; MANNOSE BINDING LECTIN 2; TRANSFORMING GROWTH FACTOR BETA1; GLUTATHIONE TRANSFERASE P1; GSTP1 PROTEIN, HUMAN; MANNOSE BINDING LECTIN; MBL2 PROTEIN, HUMAN; SERPINA1 PROTEIN, HUMAN; TGFB1 PROTEIN, HUMAN;

ADULT; ARTICLE; ATTRIBUTABLE RISK; CANADA; CASE CONTROL STUDY; CLINICAL FEATURE; CODON; CONTROLLED STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; HISTOPATHOLOGY; HUMAN; INTERNATIONAL NORMALIZED RATIO; LIVER DISEASE; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; NORTH AMERICA; ONSET AGE; OUTCOME ASSESSMENT; PORTAL HYPERTENSION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; UNITED STATES; ADOLESCENT; AGE; CHILD; CLINICAL TRIAL; GENETICS; INFANT; LIVER CIRRHOSIS; MULTICENTER STUDY; PRESCHOOL CHILD; RISK; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGE FACTORS; ALPHA 1-ANTITRYPSIN; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FEMALE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; HYPERTENSION, PORTAL; INFANT; LIVER CIRRHOSIS; LIVER DISEASES; LOGISTIC MODELS; MALE; MANNOSE-BINDING LECTIN; PEPTIDYL-DIPEPTIDASE A; POLYMORPHISM, GENETIC; RISK; TRANSFORMING GROWTH FACTOR BETA1; YOUNG ADULT;

EID: 70149106634     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2009.1295     Document Type: Article

References (41)

1. Welsh MJ, Ramsey BW, Accurso FJ, Cutting GR. Cystic fibrosis. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 8th ed. New York, NY: McGraw-Hill; 2001:5121-5188.
2. Mekus F, Ballmann M, Bronsveld I, Bijman J, Veeze H, Tummler B. Categories of deltaF508 homozygous cystic fibrosis twin and sibling pairs with distinct phenotypic characteristics. Twin Res. 2000;3(4):277-293. (Pubitemid 32126931)
3. Sontag MK, Accurso FJ. Gene modifiers in pediatrics: application to cystic fibrosis. Adv Pediatr. 2004;51:5-36. (Pubitemid 39303474)
4. Vanscoy LL, Blackman SM, Collaco JM, et al. Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med. 2007;175(10):1036-1043. (Pubitemid 46741755)
5. Drumm ML, Konstan MW, Schluchter MD, et al; Gene Modifier Study Group. Genetic modifiers of lung disease in cystic fibrosis. N Engl J Med. 2005;353(14):1443-1453.
6. Bremer LA, Blackman SM, Vanscoy LL, et al. Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet. 2008;17(14):2228-2237.
7. Dorfman R, Sandford A, Taylor C, et al. Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest. 2008;118(3):1040-1049.
8. Cohn JA, Strong TV, Picciotto MR, Nairn AC, Collins FS, Fitz JG. Localization of the cystic fibrosis transmembrane conductance regulator in human bile duct epithelial cells. Gastroenterology. 1993;105(6):1857-1864. (Pubitemid 24002805)
9. Kinnman N, Lindblad A, Housset C, et al. Expression of cystic fibrosis transmembrane conductance regulator in liver tissue from patients with cystic fibrosis. Hepatology. 2000;32(2):334-340. (Pubitemid 30616012)
10. Colombo C. Liver disease in cystic fibrosis. Curr Opin Pulm Med. 2007;13(6):529-536.
11. Feranchak AP, Sokol RJ. Cholangiocyte biology and cystic fibrosis liver disease. Semin Liver Dis. 2001;21(4):471-488. (Pubitemid 33131040)
12. Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008;371(9615):838-851.
13. Tsukada S, Parsons CJ, Rippe RA. Mechanisms of liver fibrosis. Clin Chim Acta. 2006;364(1-2):33-60.
14. Castaldo G, Fuccio A, Salvatore D, et al. Liver expression in cystic fibrosis could be modulated by genetic factors different from the cystic fibrosis transmembrane regulator genotype. Am J Med Genet. 2001;98(4):294-297. (Pubitemid 32126005)
15. Colombo C, Apostolo MG, Ferrari M, et al. Analysis of risk factors for the development of liver disease associated with cystic fibrosis. J Pediatr. 1994;124(3):393-399. (Pubitemid 24094449)
16. Feranchak AP. Hepatobiliary complications of cystic fibrosis. Curr Gastroenterol Rep. 2004;6(3):231-239.
17. Wilschanski M, Rivlin J, Cohen S, et al. Clinical and genetic risk factors for cystic fibrosis-related liver disease. Pediatrics. 1999;103(1):52-57. (Pubitemid 29281928)
18. Frangolias DD, Ruan J, Wilcox PJ, et al. Alpha 1-antitrypsin deficiency alleles in cystic fibrosis lung disease. Am J Respir Cell Mol Biol. 2003;29(3, pt 1):390-396. (Pubitemid 37093998)
19. Arkwright PD, Pravica V, Geraghty PJ, et al. Endorgan dysfunction in cystic fibrosis: association with angiotensin I converting enzyme and cytokine gene polymorphisms. Am J Respir Crit Care Med. 2003;167(3):384-389. (Pubitemid 36216420)
20. Henrion-Caude A, Flamant C, Roussey M, et al. Liver disease in pediatric patients with cystic fibrosis is associated with glutathione S-transferase P1 polymorphism. Hepatology. 2002;36(4, pt 1):913-917.
21. Gabolde M, Hubert D, Guilloud-Bataille M, Lenaerts C, Feingold J, Besmond C. The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet. 2001;38(5):310-311. (Pubitemid 32433983)
22. Colombo C, Battezzati PM, Crosignani A, et al. Liver disease in cystic fibrosis: a prospective study on incidence, risk factors, and outcome. Hepatology. 2002;36(6):1374-1382. (Pubitemid 35403528)
23. Corbett K, Kelleher S, Rowland M, et al. Cystic fibrosis-associated liver disease: a population-based study. J Pediatr. 2004;145(3):327-332. (Pubitemid 39165680)
24. Debray D, Lykavieris P, Gauthier F, et al. Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol. 1999;31(1):77-83. (Pubitemid 29287612)
25. Lamireau T, Monnereau S, Martin S, Marcotte JE, Winnock M, Alvarez F. Epidemiology of liver disease in cystic fibrosis: a longitudinal study. J Hepatol. 2004;41(6):920-925. (Pubitemid 39575658)
26. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989.
27. Purcell S, Neale B, Todd-Brown K, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559-575. (Pubitemid 47330214)
28. Armitage P. Tests for linear trends in proportions and frequencies. Biometrics. 1955;11(3):375-386.
29. Levin ML. The occurrence of lung cancer in man. Acta Unio Int Contra Cancrum. 1953;9(3):531-541.
30. Yang Q, Khoury MJ, Friedman JM, Flanders WD. On the use of population attributable fraction to determine sample size for case-control studies of gene-environment interaction. Epidemiology. 2003;14(2):161-167. (Pubitemid 40417102)
31. Levin ML, Bertell RRE. simple estimation of population attributable risk from case-control studies. Am J Epidemiol. 1978;108(1):78-79.
32. de Serres FJ, Blanco I, Fernandez-Bustillo E. PI S and PI Z alpha-1 antitrypsin deficiency worldwide: a review of existing genetic epidemiological data. Monaldi Arch Chest Dis. 2007;67(4):184-208. (Pubitemid 351188320)
33. de Serres FJ, Blanco I, Fernandez-Bustillo E. Genetic epidemiology of alpha-1 antitrypsin deficiency in North America and Australia/New Zealand: Australia, Canada, New Zealand and the United States of America. Clin Genet. 2003;64(5):382-397. (Pubitemid 37406887)
34. Eigenbrodt ML, McCashland TM, Dy RM, Clark J, Galati J. Heterozygous alpha 1-antitrypsin phenotypes in patients with end stage liver disease. Am J Gastroenterol. 1997;92(4):602-607. (Pubitemid 27184372)
35. Fischer HP, Ortiz-Pallardo ME, Ko Y, Esch C, Zhou H. Chronic liver disease in heterozygous alpha1-antitrypsin deficiency PiZ. J Hepatol. 2000;33(6):883-892.
36. Graziadei IW, Joseph JJ, Wiesner RH, Therneau TM, Batts KP, Porayko MK. Increased risk of chronic liver failure in adults with heterozygous alpha1-antitrypsin deficiency. Hepatology. 1998;28(4):1058-1063.
37. Lawless MW, Greene CM, Mulgrew A, Taggart CC, O'Neill SJ, McElvaney NG. Activation of endoplasmic reticulum-specific stress responses associated with the conformational disease Z alpha 1-antitrypsin deficiency. J Immunol. 2004;172(9):5722-5726. (Pubitemid 38542077)
38. Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006;60(2):233-238. (Pubitemid 44297600)
39. Mencin A, Seki E, Osawa Y, et al. Alpha-1 antitrypsin Z protein (PiZ) increases hepatic fibrosis in a murine model of cholestasis. Hepatology. 2007;46(5):1443-1452. (Pubitemid 350155526)
40. Regev A, Guaqueta C, Molina EG, et al. Does the heterozygous state of alpha-1 antitrypsin deficiency have a role in chronic liver diseases? interim results of a large case-control study. J Pediatr Gastroenterol Nutr. 2006;43(suppl 1):S30-S35. (Pubitemid 44014975)
41. Slieker MG, Deckers-Kocken JM, Uiterwaal CS, van der Ent CK, Houwen RH. Risk factors for the development of cystic fibrosis related liver disease. Hepatology. 2003;38(3):775-776.